Acceptability of PC-1005 gel administered rectally to HIV-1 seronegative adults at three different volume levels (MTN-037)
Multipurpose prevention technologies (MPT) have been increasingly researched for their dual-purpose preventative properties against HIV and other STIs. The acceptability of PC-1005, a topical MPT candidate, was explored among men and women participating in the MTN-037 Phase I trial at two U.S. sites (Pittsburgh, PA, and Birmingham, AL). We triangu-lated quantitative and qualitative assessments of the acceptability of three volumes (4 mL, 16 mL, 32 mL) of PC-1005 administered rectally (N = 12; 6 males, 6 females). Participants rated overall gel acceptability on a scale of 1–10, with a median of 7.17 (SD = 2.04) and had positive feelings about all three dose volumes, citing them to be very comfortable or comfortable (dose 1 = 91.7%; dose 2 = 91.7%; dose 3 = 83.3%). High acceptability of and comfort with all three dose volumes shows promise for PC-1005 as an MPT to prevent HIV and STIs, warranting future clinical development.
Bauermeister, José A., Ryan C. Tingler, Ken Ho, Rachel Scheckter, Tara McClure, Jontraye Davis, Jeanna Piper, Barbara Friedland, Stacey Edick, Mei Song, Yuqing Jiao, Craig W. Hendrix, and Craig Hoesley. 2022. "Acceptability of PC-1005 gel administered rectally to HIV-1 seronegative adults at three different volume levels (MTN-037)," AIDS Education and Prevention 34(4).